Research ArticleImmunotherapy

CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo

See allHide authors and affiliations

Science Translational Medicine  29 Apr 2015:
Vol. 7, Issue 285, pp. 285ra63
DOI: 10.1126/scitranslmed.aaa2546

Sourcing CMV immunotherapy

Immunotherapy—such as adoptive T cell therapy—is making headway in treating cancer, autoimmunity, and infectious disease. Indeed, adoptive transfer of cytomegalovirus (CMV)–specific T cells can restore immunity to the virus. However, these cells have been primarily derived from memory cells from CMV-seropositive individuals, which limits the donor pool. Now, Hanley et al. demonstrate that CMV-specific T cells can be derived from naïve T cells taken from CMV-seronegative people. These cells react to different epitopes than the memory cell–derived T cells but with similar avidity. What’s more, these cells were associated with periods of CMV-free survival when transplanted into patients. These data support expanded trials of adoptive therapy of CMV-restricted T cells from seronegative donors.

View Full Text